Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Germ Cell Neoplasms Clear all

Conditions: Malignant Melanoma
Interventions: Atezolizumab, Cobimetinib; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Scottsdale, Arizona • Aurora, Colorado • Detroit, Michigan + 3 more

Conditions: Glioblastoma, Brain Metastases
Interventions: NM404; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Melanoma
Interventions: Secukinumab Injection; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions: sunitinib malate; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
Interventions: Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide; Procedure · Radiation · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 34
States / cities: Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more

Conditions: Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Recurrent Pancreatic Cancer, Somatostatinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: Capecitabine, Temozolomide, Bevacizumab; Drug · Biological
Lead sponsor: Shaheen Shagufta; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Brain and Central Nervous System Tumors
Interventions: BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy, CCNU, BCNU 150mg/m2, BCNU 200mg/m2, TMZ 150mg/m2 six 6-week cycles, TMZ 150mg/m2 six 8-week cycles; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2018
U.S. locations: 92
States / cities: Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more

Conditions: Glioblastoma
Interventions: I-124-CLR1404; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Duarte, California • Tampa, Florida • Baltimore, Maryland + 6 more

Conditions: Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions: Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol; Drug · Biological · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor, Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage III Testicular Cancer, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions: Alvocidib Hydrochloride, Fluorouracil, Leucovorin Calcium, Oxaliplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 6 more

Conditions: Solid Tumours
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Scottsdale, Arizona • Aurora, Colorado • Fort Myers, Florida + 9 more

Conditions: Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung, Carcinoid Tumors
Interventions: Dacarbazine and bortezomib; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Richmond, Virginia

Conditions: Brain Cancer
Interventions: Fluorescein, Fluorescein + ALA; Drug
Lead sponsor: David W. Roberts; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
Interventions: ESK981; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Madison, Wisconsin

Conditions: Melanoma
Interventions: Durvalumab, Dabrafenib, Trametinib; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more

Conditions: LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor, Pediatric Tumors, Neurocutaneous Melanocytosis, Congenital Melanocytic Nevus, Arachnoid Cysts, Astrocytoma, Ependymoma, Melanoma
Interventions: Mirdametinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malignant Glioma
Interventions: D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery); Drug
Lead sponsor: Darell Bigner; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Melanoma
Interventions: Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tiragolumab, RO7247669 600 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California • Tampa, Florida + 1 more

Conditions: Glioma
Interventions: Temozolomide and Bevacizumab; Drug
Lead sponsor: Kentuckiana Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Solid Tumor, Adult
Interventions: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody; Drug · Biological
Lead sponsor: Linnaeus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more

Conditions: Glioblastoma Multiforme
Interventions: Temozolomide, radiation therapy, Ascorbic Acid; Drug · Radiation
Lead sponsor: Bryan Allen; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions: LMB-2 immunotoxin, MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant; Biological
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
Interventions: Pembrolizumab, Lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Search by objective public record fields.

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

PET/CT Imaging of Malignant Brain Tumors With 124I-NM404

IL-17 Blockade to Decrease irAEs (REPLAY)

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas

Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

D2C7-IT With Atezolizumab for Recurrent Gliomas

Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)